Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-27T22:57:21.950Z Has data issue: false hasContentIssue false
  • English
  • Français

Role of mometasone furoate aqueous nasal spray for management of adenoidal hypertrophy in children

Published online by Cambridge University Press:  18 November 2014

R Bhargava  and
A Chakravarti
R Bhargava*
Affiliation:
Department of Otorhinolaryngology and Head and Neck Surgery, Lady Hardinge Medical College and Associated Hospitals, New Delhi, Delhi, India
A Chakravarti
Affiliation:
Department of Otorhinolaryngology and Head and Neck Surgery, Lady Hardinge Medical College and Associated Hospitals, New Delhi, Delhi, India
*
Address for correspondence: Dr Rahul Bhargava, Department of Otorhinolaryngology and Head and Neck Surgery, Lady Hardinge Medical College and Associated Hospitals, Shahid Bhagat Singh Marg, New Delhi, Delhi, India Fax: 0091 1127 850 553 E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives:

To study the role of mometasone furoate aqueous nasal spray for the management of adenoidal hypertrophy in children with more than 50 per cent obstruction, and to assess its impact on change in quality of life.

Methods:

A prospective, randomised, double-blind, interventional placebo-controlled study was conducted. A total of 100 children aged 2–12 years completed treatment and follow up. The symptoms and degree of obstruction were evaluated by nasopharyngoscopy conducted pre-treatment and 24 weeks post-treatment. Subjects received mometasone furoate nasal spray at a daily dose of 200 µg for 8 weeks, followed by a dose of 200 µg on alternate days for 16 weeks. Results were compared with those of a matched control group who were given saline nasal spray.

Results:

With mometasone treatment, there was an 89.8 per cent reduction in clinical symptom score, and the degree of obstruction dropped from 87 to 72 per cent (p < 0.0001). A statistically significant change in quality of life scores was seen in patients treated with the mometasone nasal spray (score change of 37.47) as compared with those given saline nasal spray (score change of 11.25) (p = 0.0001).

Conclusion:

Mometasone nasal spray appears to be effective in treating children with obstructive adenoids.

Keywords

AdenoidsMometasone FuroateQuality Of Life
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 128 , Issue 12 , December 2014 , pp. 1060 - 1066
Copyright
Copyright © JLO (1984) Limited 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Guilleminault, C, Korobkin, R, Winkle, R. A review of 50 children with obstructive sleep apnea syndrome. Lung 1981;159:275–87CrossRefGoogle ScholarPubMed
2Bitar, MA, Rahi, A, Khalife, M, Madanat, LM. A suggested clinical score to predict the severity of adenoid obstruction in children. Eur Arch Otorhinolaryngol 2006;263:924–8Google Scholar
3Bitar, MA, Berawi, G, Youssef, M, Fuleihan, N. How frequent is adenoid obstruction? Impact on the diagnostic approach. Pediatr Int 2009;51:478–83CrossRefGoogle ScholarPubMed
4Zitt, M, Kosoglou, T, Hubbell, J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf 2007;30:317–26Google Scholar
5Sastre, J, Mosges, R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol 2012;22:1–12Google ScholarPubMed
6Cassano, P, Gelardi, M, Cassano, M, Fiorella, ML, Fiorella, R. Adenoid tissue rhinopharyngeal obstruction grading based on fiberendoscopic findings: a novel approach to therapeutic management. Int J Pediatr Otorhinolaryngol 2003;67:1303–9CrossRefGoogle ScholarPubMed
7Berlucchi, M, Salsi, D, Valetti, L, Parrinello, G, Nicolai, P. The role of mometasone furoate aqueous nasal spray in the treatment of adenoidal hypertrophy in the pediatric age group: preliminary results of a prospective, randomized study. Pediatrics 2007;119:1392–7CrossRefGoogle ScholarPubMed
8Kubba, H, Swan, IR, Gatehouse, S. The Glasgow Children's Benefit Inventory: a new instrument for assessing health-related benefit after an intervention. Ann Otol Rhinol Laryngol 2004;113:980–6CrossRefGoogle ScholarPubMed
9Goldbart, AD, Veling, MC, Goldman, JL, Li, RC, Brittian, KR, Gozal, D. Glucocorticoid receptor subunit expression in adenotonsillar tissue of children with obstructive sleep apnea. Pediatr Res 2005;57:232–6CrossRefGoogle ScholarPubMed
10Demirhan, H, Aksoy, F, Özturan, O, Yildirim, YS, Veyseller, B. Medical treatment of adenoid hypertrophy with “fluticasone propionate nasal drops”. Int J Pediatr Otorhinolaryngol 2010;74:773–6Google Scholar
11Ciprandi, G, Varricchio, A, Capasso, M, Varricchio, AM, De Lucia, A, Ascione, E et al. Intranasal flunisolide treatment in children with adenoidal hypertrophy. Int J Immunopathol Pharmacol 2007;20:833–6Google Scholar
12Lepcha, A, Kurien, M, Job, A, Jeyaseelan, L, Thomas, K. Chronic adenoid hypertrophy in children – is steroid nasal spray beneficial? Indian J Otolaryngol Head Neck Surg 2002;54:280–4CrossRefGoogle ScholarPubMed
13Cengel, S, Akyol, MU. The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. Int J Pediatr Otorhinolaryngol 2006;70:639–45CrossRefGoogle ScholarPubMed
14Bitar, MA, Mahfoud, L, Nasar, J, Dana, R. Exploring the characteristics of children with obstructive adenoid responding to mometasone furoate monohydrate: preliminary results. Eur Arch Otorhinolaryngol 2013;270:931–7CrossRefGoogle ScholarPubMed
15Rezende, RM, Silveira, F, Barbosa, AP, Menezes, UP, Ferriani, VP, Rezende, PH et al. Objective reduction in adenoid tissue after mometasone furoate treatment. Int J Pediatr Otorhinolaryngol 2012;76:829–31CrossRefGoogle ScholarPubMed
16Criscuoli, G, D'Amora, S, Ripa, G, Cinquegrana, G, Mansi, N, Impagliazzo, N et al. Frequency of surgery among children who have adenotonsillar hypertrophy and improve after treatment with nasal beclomethasone. Pediatrics 2003;111:e236–8Google Scholar